Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 341

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 341
---
 is suggested that these condensed consolidated financial statements be read in conjunction with the 2024 Annual Report. The results for the three and six months ended June 30, 2025 are not necessary indicative of the results to be expected for future periods or the full year. June 2025 Private Placement On June 2, 2025, the Company and certain accredited investors (the “Purchasers”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the “Offering”), an aggregate of 4,759,309shares of common stock together with warrants to purchase an equal number of shares of common stock at an exercise price of $ 3.3125(the “Warrants”), for an aggregate offering amount of approximately $ 12.6million. The combined effective offering price for each share and accompanying Warrant in the Offering was $ 2.65. F-98

Pursuant to the Securities Purchase Agreement, each Purchaser was obligated to purchase such Purchaser’s respective investment in the Offering in four equal tranches, as follows:

| • |     | $2.23million was purchased on June 2, 2025 (the “Initial Closing”); |

| • |     | $2.23million was purchased on June 9, 2025, following the Company’s notification to the Purchasers that the Food and Drug Administration (FDA) has notified the Company that the Company is no longer subject to the partial clinical hold set forth in the FDA’s Partial Clinical Hold letter to the Company dated January 24, 2024, with respect to the Company’s planned Phase 3 trial ofIFx-2.0; |

| • |     | $2.23million was purchased on June 24, 2025, following the Company’s notification to the Purchasers that the Phase 3 trial forIFx-Hu2.0(the “Phase 3 Trial”) had been initiated; and |

| • |     | $2.23million was purchased on June 30, 2025, following the Company’s notification to the Purchasers that all material conditions for the closing of the Company’s merger transaction with Kineta have been satisfied (other than conditions that cannot be satisfied until on or immediately before the closing of the Kineta Merger) and that the Company is prepared to close the Kineta Merger. |

**In addition to the approximately $ 8